# Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

> **NCT04116320** · PHASE1 · TERMINATED · sponsor: **Craig L Slingluff, Jr** · enrollment: 5 (actual)

## Conditions studied

- Melanoma
- Breast Cancer
- Merkel Cell Carcinoma
- Squamous Cell Cancer
- Non Small Cell Lung Cancer
- Cervical Cancer
- Urothelial Carcinoma
- Ovarian Cancer
- Hepatocellular Carcinoma
- Small-cell Lung Cancer
- Microsatellite Instability High
- Gastric Cancer
- Esophageal Cancer

## Interventions

- **DEVICE:** Echopulse
- **DRUG:** Poly ICLC
- **DRUG:** Standard of Care PD-1 Therapy

## Key facts

- **NCT ID:** NCT04116320
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-21
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Unable to enroll enough patients to complete targeted enrollment in a reasonable time.
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116320, "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04116320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*